Shape the Future of Cancer Therapeutics
Drive global licensing-out transactions and strategic partnerships for a leading oncology pipeline. This role requires a strong combination of oncology drug development knowledge, transaction execution expertise, commercial acumen, and senior-level partnering capabilities. Work closely with the CBO, executive management, and cross-functional teams to maximize the global commercial value of oncology assets.
Primary Responsibilities
- Lead end-to-end global licensing-out transactions for oncology assets, from partner identification and initial engagement through due diligence, term sheet negotiation, definitive agreements, and deal closing.
- Advance ongoing transactions from the Term Sheet stage toward definitive licensing agreements and successful deal execution.
- Develop asset-specific licensing strategies based on clinical data, mechanism of action, competitive positioning, target patient populations, and market opportunities.
- Lead negotiations on upfront payments, development and regulatory milestones, royalties, territorial rights, exclusivity, intellectual property, and development and commercialization responsibilities.
- Develop transaction structures that optimize asset value while addressing commercial, clinical, regulatory, and execution risks.
- Identify and engage potential partners, including multinational pharmaceutical companies, oncology-focused biotechnology companies, and regional pharmaceutical partners.
- Build senior-level relationships with global oncology business development, licensing, and therapeutic area leadership teams.
- Represent the company in strategic partnering meetings, international oncology conferences, and senior-level licensing negotiations.
- Analyze oncology treatment landscapes, standards of care, competitive pipelines, clinical data, unmet medical needs, and commercial opportunities.
- Assess the differentiation and partnering potential of pipeline assets based on efficacy, safety, biomarker strategies, target populations, and competitive positioning.
- Develop commercial assessments and transaction valuation models in collaboration with clinical, scientific, and finance teams.
- Monitor comparable oncology licensing transactions and market trends to inform negotiation strategies and deal structures.
- Provide recommendations on asset prioritization, licensing timing, target markets, and partner selection.
- Advise the CBO and executive management on oncology pipeline monetization, licensing strategy, partnership opportunities, and transaction priorities.
- Lead high-level commercial negotiations with prospective partners and communicate transaction progress and risks to senior management.
- Contribute to the global growth strategy through strategic partnerships and value-maximizing licensing transactions.
Skills & Requirements
- Advanced degree in life sciences, medicine, pharmacy, oncology, biotechnology, or a related field. A PhD is preferred; an MBA is an advantage.
- Proven years of relevant experience in biopharmaceutical business development, licensing, corporate development, or strategic partnering, with seniority appropriate to Director - Executive Director level.
- Strong understanding of oncology drug development, clinical trial design, competitive landscapes, and the commercial considerations relevant to oncology assets.
- Demonstrated experience leading or materially contributing to oncology licensing-out transactions, including term sheet negotiation, due diligence, and definitive agreement execution.
- Established relationships with pharmaceutical and biotechnology companies active in oncology development and commercialization.
- Strong knowledge of licensing economics, transaction structuring, intellectual property, clinical and regulatory milestones, and global commercialization rights.
- Proven ability to lead complex cross-border negotiations and coordinate multidisciplinary transaction teams.
- Excellent strategic thinking, negotiation, communication, and stakeholder management skills.
- Fluency in English is required; Mandarin Chinese proficiency is preferred.
Compensation
$240,000 to $390,000 per annum.